These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37467878)

  • 1. Immunogenicity risk assessment of synthetic peptide drugs and their impurities.
    De Groot AS; Roberts BJ; Mattei A; Lelias S; Boyle C; Martin WD
    Drug Discov Today; 2023 Oct; 28(10):103714. PubMed ID: 37467878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
    Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
    Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Mattei AE; Gutierrez AH; Martin WD; Terry FE; Roberts BJ; Rosenberg AS; De Groot AS
    Front Drug Discov (Lausanne); 2022; 2():. PubMed ID: 36945694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Related impurities in peptide medicines.
    D'Hondt M; Bracke N; Taevernier L; Gevaert B; Verbeke F; Wynendaele E; De Spiegeleer B
    J Pharm Biomed Anal; 2014 Dec; 101():2-30. PubMed ID: 25044089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides.
    Wu LC; Chen F; Lee SL; Raw A; Yu LX
    Int J Pharm; 2017 Feb; 518(1-2):320-334. PubMed ID: 28027918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis.
    Vial J; Cohen M; Sassiat P; Thiébaut D
    Curr Med Res Opin; 2008 Jul; 24(7):2019-33. PubMed ID: 18544188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical considerations for characterization of generic peptide product: A regulatory insight.
    Kuril AK; Saravanan K; Subbappa PK
    Anal Biochem; 2024 Nov; 694():115633. PubMed ID: 39089363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.
    Klein K; Borchard G; Shah VP; Flühmann B; McNeil SE; de Vlieger JSB
    Ann N Y Acad Sci; 2021 Oct; 1502(1):5-13. PubMed ID: 34296458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of innate immune response modulating impurities in glucagon for injection.
    Han Q; Bao Z; Luo MZ; Zhang JY
    PLoS One; 2022; 17(11):e0277922. PubMed ID: 36409759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.
    Staby A; Steensgaard DB; Haselmann KF; Marino JS; Bartholdy C; Videbæk N; Schelde O; Bosch-Traberg H; Spang LT; Asgreen DJ
    Pharm Res; 2020 Jun; 37(7):120. PubMed ID: 32514880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generics: keep a balanced view.
    Prescrire Int; 2014 Feb; 23(146):52-5. PubMed ID: 24669392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvals.
    Klein K; Heisterberg J; Stolk P
    Front Med (Lausanne); 2024; 11():1335928. PubMed ID: 38681047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.
    Son KB
    Front Public Health; 2021; 9():654952. PubMed ID: 33889560
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.
    Wittayanukorn S; Rosenberg M; Schick A; Hu M; Wang Z; Babiskin A; Lionberger R; Zhao L
    Ther Innov Regul Sci; 2020 Nov; 54(6):1372-1381. PubMed ID: 32495310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of purity profiles of generic lisinopril tablets marketed in Croatia.
    Benković G; Sokolić M; Cudina B; Zulj RT; Tomić S
    Coll Antropol; 2013 Jun; 37(2):601-6. PubMed ID: 23941010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
    Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.